Indications for Pancuronium Bromide Injection:
Adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Adults and Children:
Individualize. Adjunct to anesthesia: Initially 0.04 to 0.1mg/kg, then may use incremental doses starting at 0.01mg/kg. Relaxation for intubation: inject bolus dose of 0.06 to 0.1mg/kg. Neonates: give test dose 1st of 0.02mg/kg. Monitor with a peripheral nerve stimulator to avoid overdosage.
To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Myasthenia gravis or myasthenic (Eaton-Lambert) syndrome (do test dose and monitor). Pre-existing pulmonary disease. Renal disease or failure. Hepatic and/or biliary tract disease. Cardiovascular disease and edematous state. Long-term use in I.C.U. Immobilized for long periods. Severe obesity or neuromuscular disease; monitor airway and ventilation. Electrolyte imbalance. Adrenal cortical insufficiency. Neonates. Elderly. Pregnancy (Cat.C). Nursing mothers.
Neuromuscular blocker (nondepolarizing).
Prior administration of succinylcholine may potentiate effects (delay dose or give pancuronium 1st). Potentiated by volatile inhalational anesthetics (eg, enflurane, isoflurane, halothane), aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate, magnesium salts. Significant additive effects with pancuronium bromide-metocurine and pancuronium bromide-d-tubocurarine combinations than with the individual drugs given alone. Potential severe ventricular arrhythmias in concomitant with tricyclics and halothane. Caution with quinidine injection.
Skeletal muscle weakness or prolonged paralysis, circulatory effects, salivation, transient rash; rare: hypersensitivity reactions.
Formerly known under the brand name Pavulon.